ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR Convergence 2024

Abstract Number: 1158

Microvascular Differences Between Cancer and Non-cancer Anti-transcriptional Intermediary Factor 1 Gamma Antibody (anti-TIF1-γ) Associated Dermatomyositis Patients

Sehreen Mumtaz1, Megan Sullivan2, Maximiliano Diaz Menindez3, Emily Craver4 and Florentina Berianu5, 1Mayo Clinic, Florida, Jacksonville, FL, 2Mayo Clinic Arizona, Scottsdale, AZ, 3Mayo Clinic School of Graduate Medical Education, Phoenix, AZ, 4Mayo Clinic Florida, Jacksonville, FL, 5mayo clinic, Ponte Vedra Beach, FL

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR Convergence 2024

Keywords: dermatomyositis, Oncology, prognostic factors

Session Information

Date: Sunday, November 17, 2024

Title: Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster II

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Nailfold videocapillaroscopy (NVC) findings have been studied to differ in different subsets of myositis-specific autoantibodies (MSAs) associated inflammatory myopathies. Prior investigations observed a statistically significant reduced NVC score and greater capillary loss with presence of anti-transcriptional intermediary factor 1 gamma antibody (TIF). We aim to study differences in NVC findings amongst patients with TIF-associated dermatomyositis who developed cancer compared to patients who did not develop cancer in order to identify any prognostic NVC feature. This is the first study investigating this hypothesis to our knowledge.

Methods: Retrospective review of all patients with TIF dermatomyositis at Mayo Clinic from January 1st, 2010, till May 16th, 2024, was conducted. Adult patients >18 years of age were included and demographics, clinical features, serologies, date of diagnosis, laboratory data, last follow-up, response to treatment, NVC, and outcome were recorded. NVC was performed on all eight nailbeds using the 2nd-5th digits of both hands. Capillary morphology, density, organization, microhemorrhages, and ramifications of each nailbed were compared amongst TIF dermatomyositis with and without cancer. The study was approved by the Mayo Clinic Institutional Review Board.

Results: 21 patients with TIF dermatomyositis were identified and NVC was performed on a total of 19 patients. 5 (26.3%) patients had cancer, 94.7% were female and there were no significant differences in race with 100% Caucasian patients (Table 1).  Mean age was 56 years in the cancer subset and 58 years in the non-cancer group.  TIF dermatomyositis patients with cancer were more likely to have inflammatory arthritis (80% vs 14%), muscle weakness (80% vs 64%) and neurological involvement while non-cancer subset had more skin involvement (93% vs 40%, Table 1). TIF dermatomyositis subset with cancer had higher NVC scores of capillary microhemorrhages and ramifications compared to patients without cancer (Table 2). Non-cancer TIF dermatomyositis patients had more enlarged ( >20 but < 50 microns) and giant ( >50 microns) capillaries with higher disorganization (Table 2).

Conclusion: TIF dermatomyositis patients with cancer were more likely to present with inflammatory arthritis, muscle weakness and neurological symptoms while patients without cancer had more frequent skin involvement. NVC differences between cancer and non-cancer TIF dermatomyositis were observed indicating microvascular differences with a potential for predicting cancer development and need to be further investigated.

Supporting image 1

Table 1: Patient Characteristics [The sample median (Q1, Q3) is given for continuous variables, while categorical and ordinal variables are reported as frequency (percentage)].

Supporting image 2

Table 2: Nailfold Videocapillaroscopy Results [Median (Q1, Q3) scores are shown separately for each group. The adjusted difference (Cancer patients vs. Non-cancer patients) in NVC scores and corresponding 95% confidence intervals were estimated from linear regression models adjusting for age].

Supporting image 3

Figure 1: Jitter Plot of Nailfold Videocapillaroscopy Scores


Disclosures: S. Mumtaz: None; M. Sullivan: None; M. Diaz Menindez: None; E. Craver: None; F. Berianu: None.

To cite this abstract in AMA style:

Mumtaz S, Sullivan M, Diaz Menindez M, Craver E, Berianu F. Microvascular Differences Between Cancer and Non-cancer Anti-transcriptional Intermediary Factor 1 Gamma Antibody (anti-TIF1-γ) Associated Dermatomyositis Patients [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/microvascular-differences-between-cancer-and-non-cancer-anti-transcriptional-intermediary-factor-1-gamma-antibody-anti-tif1-%ce%b3-associated-dermatomyositis-patients/. Accessed .

ACR Meeting Abstracts - https://acrabstracts.org/abstract/microvascular-differences-between-cancer-and-non-cancer-anti-transcriptional-intermediary-factor-1-gamma-antibody-anti-tif1-%ce%b3-associated-dermatomyositis-patients/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology